Dec 14, 2017 Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
Sep 11, 2017 Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer
Sep 05, 2017 Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Mar 20, 2017 Checkpoint Therapeutics to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2017